Cohort of Premature Newborns for Charaterization of the Digestive Microbiota in Ulcerative Necrotizing Enterocolitis in Premature Infants (CortECS)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Monitoring of a cohort of premature newborns with constitution of a collection of biological samples.
follow-up of newborns from birth up to 37 weeks of amenorrhea. The medical care of children will not be affected by their participation in the research.
- Sampling of amniotic fluid at the time of rupture of the water bag
- Sampling of the blood contained in the umbilical cord after clamping and section of the cord
- Sampling of meconium during the first 24 hours of life in intensive care / neonatal / maternity ward
- Collection of a daily stool sample until the end of hospitalization and when a NEC occurs
- Sampling of gastric residues during an episode of NEC
- Taking a daily sample of the newborn's enteral food
- Sampling of 500 µL of additional blood weekly during the punctures made for the treatment
- Daily statement of constants
Record of all complications related to prematurity (HIV, bronchodysplastic, sepsis)
- Blood analysis: CBC, platelets and CRP (data analyzed as part of the treatment). Specific analyzes for research will assess: the level of tryptase, IL4 and TLR4. The samples will be stored and analyzed in the immunology laboratory of the CHU Clermont Ferrand (Pr B. Evrard)
- Analysis of the meconium sample and each stool emitted during hospitalization, and during an episode of ECUN
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Lise Laclautre
- Phone Number: 04 73 75 11 95
- Email: promo_interne_drci@chu-clermontferrand.fr
Study Locations
-
-
-
Clermont-Ferrand, France
- CHU clermont-ferrand
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- born prematurely < 37 weeks of amenorrhea at the maternity ward of the CHU
- affiliated with a social security regime
- the holders of parental authority are able to give an informed consent to participate in the research
Exclusion Criteria:
- fetal pathology
- newborns whose holders of parental authority are under guardianship or under the age of 18
- refusal of participation by holders of parental authority
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: NEC
premature newborns developing a NEC
|
weekly Blood sample and daily Stools sample during 12 weeks + Blood and stool sample during NEC
|
|
Active Comparator: Healthy control
premature newborns without NEC
|
weekly Blood sample and daily Stools sample during 12 weeks
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
comparison of volatolomics results of the gut microbiota
Time Frame: Immediatly after the intervention
|
Characterization of the gut microbiota using a capture method by hybridization of the gene encoding 16S rRNA
|
Immediatly after the intervention
|
|
comparison of microbiological results of the gut microbiota
Time Frame: Immediatly after the intervention
|
Characterization of the gut microbiota using a capture method by hybridization of the gene encoding 16S rRNA
|
Immediatly after the intervention
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fungal microbiota
Time Frame: Immediatly after the intervention
|
Comparison of the fungal microbiota on 10 NECS and 10 healthy babies
|
Immediatly after the intervention
|
|
Tryptasemia
Time Frame: Day 1, Day 3, Immediatly after the intervention
|
measurement of blood tryptasemia
|
Day 1, Day 3, Immediatly after the intervention
|
|
environmental xenobiotics
Time Frame: Day 1
|
measurement of titane and silicia levels in placental and meconium assays
|
Day 1
|
|
Milk protein composition
Time Frame: daily for 12 weekd
|
milk protein determination
|
daily for 12 weekd
|
|
Milk lipid composition
Time Frame: daily for 12 weekd
|
milk lipid determination
|
daily for 12 weekd
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Intestinal Diseases
- Obstetric Labor, Premature
- Obstetric Labor Complications
- Pregnancy Complications
- Digestive System Diseases
- Gastrointestinal Diseases
- Gastroenteritis
- Enterocolitis
- Premature Birth
- Enterocolitis, Necrotizing
Other Study ID Numbers
Other Study ID Numbers
- RBHP 2021 PONS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.